Published in Endocrinology on April 01, 2000
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol (2006) 1.40
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther (2010) 1.02
Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos (2012) 1.00
Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res (2012) 0.89
Evidence for central regulation of glucose metabolism. J Biol Chem (2013) 0.85
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev (2016) 0.78
Antidiabetic treatment, stroke severity and outcome. World J Diabetes (2014) 0.78
Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy. Clin Med Pathol (2008) 0.77
Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra. J Neurodegener Dis (2013) 0.75
Exenatide Alters Gene Expression of NCAM, ICAM, and VCAM in the Hippocampus of Type 2 Diabetic Model Mice. Med Sci Monit (2016) 0.75
Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine. Oncol Lett (2017) 0.75
Reminders to physicians from an introspective computer medical record. A two-year randomized trial. Ann Intern Med (1984) 15.06
Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature (1998) 7.36
Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 6.41
A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 6.03
Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet (1987) 4.97
ACTIVE: a cognitive intervention trial to promote independence in older adults. Control Clin Trials (2001) 4.27
Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem (1984) 4.20
Stimulation of steroidogenesis in tissue culture by enterotoxigenic Escherichia coli and its neutralization by specific antiserum. Infect Immun (1974) 4.19
Bullying in schools: self reported anxiety, depression, and self esteem in secondary school children. BMJ (1998) 4.14
Some characteristics of homosexual men. Br J Vener Dis (1976) 4.00
Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem (1988) 3.91
The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology (2000) 3.80
Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 3.62
A glucagonoma syndrome. Lancet (1974) 3.56
Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A (1983) 3.52
Conformational change in the DNA associated with an unusual promoter mutation in a tRNA operon of Salmonella. Cell (1984) 3.44
Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology (1985) 3.36
Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning. Nat Neurosci (1998) 3.33
Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet (1973) 3.22
Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance. Lancet (1976) 3.08
Distribution and release of human pancreatic polypeptide. Gut (1976) 3.02
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol (1987) 2.87
Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology (2005) 2.80
Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut (1971) 2.75
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Neuron-specific enolase is produced by neuroendocrine tumours. Lancet (1981) 2.63
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem (2001) 2.58
Breast vs bottle: endocrine responses are different with formula feeding. Lancet (1980) 2.52
Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev (2000) 2.52
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Measurement of fasting and postprandial plasma VIP in man. Gut (1978) 2.48
Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest (1999) 2.48
Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child (1981) 2.36
Genetic factors in determining bone mass. J Clin Invest (1973) 2.35
Urease tests for Campylobacter pylori: care in interpretation. J Clin Pathol (1988) 2.35
Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol (2004) 2.27
Gut-hormone profile in coeliac disease. Lancet (1978) 2.25
Saturation of fat and cholecystokinin release: implications for pancreatic carcinogenesis. Lancet (1989) 2.25
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab (2001) 2.24
Long-term health effects in hamsters and rats exposed chronically to man-made vitreous fibres. Ann Occup Hyg (1987) 2.23
Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol (2001) 2.20
Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun (1979) 2.16
Gut hormones and appetite control. Gastroenterology (2007) 2.16
A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology (1998) 2.14
Pancreatic polypeptide in insulinomas, gastrinomas, vipomas, and glucagonomas. Lancet (1976) 2.13
The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man. Gut (1984) 2.11
Neuropeptide Y distribution in the rat brain. Science (1983) 2.10
New approach to assessment of cardioselectivity of beta-blocking drugs. Br Med J (1974) 2.06
An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man. Br J Clin Pharmacol (1975) 2.05
Epithelial-mesenchymal signaling during the regionalization of the chick gut. Development (1998) 2.05
Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet (1975) 2.04
The role of the sympathetic innervation in the control of plasma glucagon concentration in the calf. J Physiol (1973) 2.01
The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals. Cell (1998) 1.95
Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) (1983) 1.93
Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg (2006) 1.91
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes (1999) 1.90
Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest (1997) 1.89
Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. J Neurosci (1984) 1.88
Encouraging primary care physicians to help smokers quit. A randomized, controlled trial. Ann Intern Med (1989) 1.86
Effects of stimulation of the chorda tympani in bursts on submaxillary responses in the cat. J Physiol (1982) 1.84
Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology (2009) 1.83
Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet (1979) 1.81
Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am J Pathol (1990) 1.80
Increased leptin levels in serum and peritoneal fluid of patients with pelvic endometriosis. J Clin Endocrinol Metab (2000) 1.75
Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet (1977) 1.75
Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology (1997) 1.74
The effect of truncal and selective vagotomy on the release of pancreatic glucagon, insulin and enteroglucagon. Br J Surg (1974) 1.73
Bombesin-like immunoreactivity in the lung. Nature (1978) 1.73
Localization of insulinomas by selective intraarterial calcium injection. J Clin Endocrinol Metab (1996) 1.72
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab (2003) 1.71
Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology (1980) 1.70
Bromocriptine treatment of acromegaly. Br Med J (1975) 1.70